OXFORD, UK AND CAMBRIDGE, MA - Moderna Inc. (NASDAQ:MRNA) and the University of Oxford announced today that their Phase 1/2 study of mRNA-4194, an investigational cancer vaccine for Lynch syndrome, received authorization from the UK’s Medicines and Healthcare products Regulatory Agency. The biotech company, valued at $18.9 billion, has seen its stock surge 73% over the past year.
Lynch syndrome is an inherited condition affecting 1 in 300 people that increases the risk of several cancer types, including colorectal, endometrial, ovarian, stomach and prostate cancers. The condition is caused by alterations in genes responsible for repairing DNA, leading to lifetime cancer risk of up to 80%.
The vaccine is designed to generate immune responses against selected targets associated with early cancer development in people with Lynch syndrome. mRNA-4194 represents Moderna’s first investigational cancer prevention program.
The Phase 1/2 study, funded by Moderna and sponsored by the University of Oxford, will administer mRNA-4194 to participants with Lynch syndrome to assess safety, characterize immune response and determine the optimal dose for further testing. The companies anticipate the first patient to be dosed this summer. The second phase will expand enrollment across multiple centers in the UK and is expected to begin in 2027, according to the press release statement.
Professor David Church, lead investigator in the trial from the University of Oxford’s Centre for Human Genetics, stated the trial "represents a meaningful step in our efforts to prevent Lynch syndrome-associated cancers before they develop."
The clinical trial is part of a 10-year strategic partnership between Moderna and the UK Government established in 2022. The collaboration has delivered more than 20 clinical trials across 135 centers, involving more than 14,500 participants to date. According to InvestingPro analysis, which currently rates the stock as overvalued, Moderna shows a large price uptick over the last six months. Investors can access 8 additional InvestingPro Tips and a comprehensive Pro Research Report for deeper analysis.
Current care options for people with Lynch syndrome remain limited to regular surveillance, with low-dose aspirin and surgery used in select cases.
In other recent news, Moderna has announced early-stage research into an mRNA-based hantavirus vaccine, in collaboration with Korea University under its mRNA Access Program. This development comes amid reports of hantavirus cases, including 11 cases on a cruise ship reported by the World Health Organization, though no broader outbreak is expected. Additionally, Moderna’s board of directors approved an amendment to its bylaws, designating federal district courts as the exclusive forum for certain legal complaints, aligning with recent changes in Delaware’s corporate law.
In another update, Moderna held its 2026 Annual Meeting of Stockholders, where all agenda items were voted on with a quorum present. UBS has reiterated a Neutral rating for Moderna, citing the company’s Phase III INT adjuvant melanoma interim analysis as a significant catalyst expected in 2026. This analysis is anticipated to occur around October or November of that year. These recent developments highlight Moderna’s ongoing research initiatives and corporate governance adjustments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for MRNA plus thousands of other stocks and find your next hidden gem with massive upside.